BDBM509589 US11364246, Example 3.9b::US20200361871A1, Example 3.9b

SMILES CC(C)(C)NC(=O)c1cc(NC(=O)C2CCc3ccc(O)cc23)ccn1

InChI Key InChIKey=RAIHYJSFZXTTHN-UHFFFAOYSA-N

Data  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 509589   

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509589(US20200361871A1, Example 3.9b | US11364246, Exampl...)
Affinity DataEC50:  960nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
Go to US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509589(US20200361871A1, Example 3.9b | US11364246, Exampl...)
Affinity DataEC50:  960nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
Go to US Patent